References
- Clement B. (2002). Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines. Drug Metab Rev 34:565–79
- Clement B, Mau S, Deters S, Havemeyer A. (2005). Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N-hydroxylated prodrugs benzami-doxime, guanoxabenz, and Ro 48-3656 ([[1-[(2s)-2-[[4-[(hydroxyamino)iminomethyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]-acetic acid). Drug Metab Dispos 33:1740–7
- Ertongur S, Lang S, Mack B, et al. (2004). Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer 110:815–24
- Gruenewald S, Wahl B, Bittner F, et al. (2008). The fourth molybdenum containing enzyme mARC: cloning and involvement in the activation of N-hydroxylated prodrugs. J Med Chem 51:8173–7
- Havemeyer A, Bittner F, Wollers S, et al. (2006). Identification of the missing component in the mitochondrial benzamidoxime prodrug-converting system as a novel molybdenum enzyme. J Biol Chem 281:34796–802
- Havemeyer A, Grunewald S, Wahl B, et al. (2010). Reduction of N-hydroxy-sulfonamides, including N-hydroxy-valdecoxib, by the molybdenum-containing enzyme mARC. Drug Metab Dispos 38:1917–21
- Havemeyer A, Lang J, Clement B. (2011). The fourth mammalian molybdenum enzyme mARC: current state of research. Drug Metab Rev 43:524–39
- Heinemann V, Ebert M, Pinter T, et al. (2010). Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced non-metastatic pancreatic cancer. Ann Oncol 21:226
- Hovius R, Lambrechts H, Nicolay K, De Kruijff B. (1990). Improved methods to isolate and subfractionate rat liver mitochondria. Lipid composition of the inner and outer membrane. Biochim Biophys Acta 1021:217–26
- Kotthaus J, Steinmetzer T, van de Locht A, Clement B. (2011a). Analysis of highly potent amidine containing inhibitors of serine proteases and their N-hydroxylated prodrugs (amidoximes). J Enzyme Inhib Med Chem 26:115–22
- Kotthaus J, Wahl B, Havemeyer A, et al. (2011b). Reduction of N(omega)-hydroxy-l-arginine by the mitochondrial amidoxime reducing component (mARC). Biochem J 433:383–91
- Krompholz N, Krischkowski C, Reichmann D, et al. (2012). The mitochondrial amidoxime reducing component (mARC) is involved in detoxification of n-hydroxylated base analogues. Chem Res Toxicol 25:2443–50
- Laemmli UK. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–5
- Meyer JE, Brocks C, Graefe H, et al. (2008). The oral serine protease inhibitor WX-671 – first experience in patients with advanced head and neck carcinoma. Breast Care 3:20–4
- Monder C. (1967). Discussion: effect of DMSO on enzyme activity. Ann NY Acad Sci 141:300–1
- Pillay V, Dass CR, Choong PF. (2007). The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 25:33–9
- Rautio J, Kumpulainen H, Heimbach T. (2008). Prodrugs: design and clinical applications. Nat Rev Drug Discov 7:255–70
- Setyono-Han B, Stürzebecher J, Schmalix WA, et al. (2005). Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UKI. Thromb Haemost 4:779–86
- Wahl B, Reichmann D, Niks D, et al. (2010). Biochemical and spectroscopic characterization of the human mito-chondrial amidoxime reducing components hmARC-1 and hmARC-2 suggests the existence of a new molybdenum enzyme family in eukaryotes. J Biol Chem 285:37847–59